Introduction
Aplidint is a cyclic depsipeptide isolated from the tunicate Aplidium albicans (Sakai et al., 1996) that has very potent cytotoxic activity against many tumor cell types (Lobo et al., 1997; Depenbrock et al., 1998) and strong antitumor activity in xenograft models (Faircloth et al., 1997) . Aplidint is presently undergoing Phase II clinical trials in a variety of tumors.
Early studies indicated that Aplidint exerts an antiproliferative effect through the inhibition of protein synthesis and reduction of ornithine decarboxylase activity (Urdiales et al., 1996; Go´mez-Fabre et al., 1997) . However, further analysis questioned the relevance of these findings and showed that it induces apoptosis unrelated to macromolecular synthesis inhibition or putrescine levels (Erba et al., 2002) . In addition, Aplidint-induced apoptosis in several cultured cells is independent of their p53 tumor suppressor status (Erba et al., 1999 (Erba et al., , 2002 Yao, 2003) . In human leukemia MOLT-4 cells, Aplidint inhibits vascular endothelial growth factor (VEGF) secretion and autocrine VEGF-VEGFR-1 stimulation (Broggini et al., 2003) . In these cells, Aplidint causes cell cycle phase perturbations, though no effect on cyclin-dependent kinases was detected (Erba et al., 2002) .
We have previously reported that Aplidint induces caspase-dependent and -independent apoptosis at nanomolar concentrations with no changes in cell cycle phases in human MDA-MB-231 breast cancer and several renal cancer cells (Cuadrado et al., 2003) . In these cell systems it causes a rapid increase in the phosphorylation of epidermal growth factor receptor (EGFR) and the activation of the kinases Src, JNK and p38MAPK (Cuadrado et al., 2003) . These effects are caused by a depletion of cellular glutathione (GSH), as they are all attenuated by addition of GSH, Ebselen or N-acetylcysteine. Likewise, in HeLa cells Aplidint activates EGFR, JNK and p38MAPK, and rapidly induces the apoptotic mitochondrial pathway thus promoting cytochrome release from the mitochondria and caspase-3 activation. In this cell line, Aplidint also induces ERK and PKCd (Garcı´a-Ferna´ndez et al., 2002) . In human T-lymphoid Jurkat, promyelocytic HL-60 and erythroleukemic HEL cells Aplidint promotes both, the mitochondrial and Fas/CD95 receptor apoptotic pathways (Gajate et al., 2003) .
Here, we examine the molecular mechanism of action of Aplidint. First, we show that it induces rapidly a series of genes of the JUN and FOS families, and p65/ RELA in MDA-MB-231 cells, which leads to a transient increase in AP-1 and nuclear factor kappa factor (NFkB) activity. Second, by studying a series of genetically deficient cells, we identify JNK as the critical primary target of Aplidint action.
Results

Aplidint induces a rapid and transient activation of AP-1 and NF-kB
Aplidint induces apoptosis of human MDA-MB-231 breast cancer cells with IC 50 in the nanomolar range (Cuadrado et al., 2003) . First, we examined whether continuous treatment is necessary for its action. Short (5-15 min) treatments caused half-maximal reduction in cell survival compared with permanent drug treatment (not shown), indicating that the cytotoxic activity of Aplidint is triggered rapidly and does not require the continuous presence of the drug.
Next, we studied whether Aplidint could induce genes of the activator protein-1 (AP-1) and (NF-kB) families of transcription factors, which are implicated in the early cellular response to many stress conditions (Ly and Karin, 1998; Bowie and O'Neill, 2000; Shaulian and Karin, 2002) . All genes of the AP-1 constituents JUN and FOS proto-oncogenes subfamilies (but FRA-2) were induced by Aplidint (Figure 1a) . Concordantly, nuclear AP-1 activity analysed by protein binding to a consensus DNA element was increased upon Aplidint treatment of MDA-MB-231 cells (Figure 1b) . Likewise, Aplidint transiently increased NF-kB activity and DNA binding as measured in transactivating assays ( Figure 2a ) and electrophoretic mobility shift assays (Figure 2b ). In line with this, both RNA and protein levels of p65/RELA, a major component of NF-kB dimers, strongly increased upon Aplidint treatment (Figure 2c ). In contrast, no changes were found in the case of p50, partner of p65/ RELA (not shown). Many NF-kB activators induce IkB kinase (IKK)-phosphorylation of IkBa, the major inhibitor of NF-kB activity, which is followed by its degradation by the proteasome and NF-kB nuclear translocation and DNA binding. Unexpectedly, Aplidint did not decrease the cellular content of the IkBa (Figure 2d , upper panel), and thus caused a weak increase in the phosphorylation of its critical IKK target serine residues (Ser 32/36 ), which could only be detected by coupled immunoprecipitation and Western blot ( Figure 2d , lower panel). As IkBa is also phosphorylated at Tyr 42 upon cell exposure to oxidative stresses or tyrosine phosphatase inhibitors leading to NF-kB activation without IkBa degradation (Imbert et al., 1996; Singh et al., 1996) , we explored the possibility that Aplidint could affect this residue. However, Aplidint did not induce Tyr 42 IkBa phosphorylation (not shown).
We used inhibitors of the EGFR (AG1478), Src (PP2) and JNK/p38MAPK (SB203580, which inhibits both kinases in this cell line, Cuadrado et al., 2003) to study the mechanism of induction of AP-1 and p65/RELA genes by Aplidint. c-FOS induction required the activity of all these kinases (Figure 2e ). In contrast, c-JUN induction required Src and JNK/p38MAPK but not EGFR activity, and that of p65/RELA was only partially dependent on each single kinase (Figure 2e ).
Aplidint has complex regulatory effects on MYC expression
MYC oncogene regulates growth and survival depending on the cellular type and context. It is frequently altered or deregulated in human cancer and its overexpression has been proposed to promote apoptosis by de-estabilizing mitochondrial integrity (Juin et al., 1999) . As Myc protein is phosphorylated by JNK (Noguchi et al., 1999) and this kinase is activated by Aplidint (Cuadrado et al., 2003) , we explored the possibility that MYC expression could be regulated by the drug. Aplidint induced a transient increase in MYC RNA followed by strong downregulation (Figure 3a) . Moreover, the rapid increase in RNA level was concomitant to a reduction in MYC protein (Figure 3b ) which was insensitive to cotreatment with proteasome (MG132, lactacystin) and lysosomal (E64) inhibitors, suggesting a translation blockade (not shown).
JNK activity is critical for Aplidint-induced apoptosis
We aimed to characterize the crucial mediator of Aplidint-induced apoptosis. First, we found that SB203580, but not PP2 or LY294002, a phosphatidylinositol-3-kinase inhibitor, blocked EGFR phosphorylation by Aplidint in MDA-MB-231 cells and wt MEFs (Figure 4) . Conversely, Aplidint did not induce EGFR phosphorylation in MEFs lacking JNK (jnk1/2 À/À , which do not express any JNK isoform) or c-jun (cjun (Figure 4) . Together, these results suggested that JNK activation and c-jun induction are previous to EGFR activation by the drug. Additionally, JNK activation is previous to caspase activation, as it was not altered by pretreatment with the general caspase inhibitor Z-VAD (not shown).
To further investigate this issue, we used a series of genetically deficient cells, as this overcomes the lack of specificity of protein kinase inhibitors and the variability of transfection assays using dominant-negative kinase mutants (muts). MEFs deficient for src, yes and fyn (src
), which showed normal activation of JNK and p38MAPK by Aplidint (Figure 5a ), and also those deficient for p38MAPK (p38a In contrast, jnk1/2 À/À MEFs were much less sensitive to Aplidint (IC 50 4500 nM) (Figure 6a, b) . Since c-Jun is a major target of JNK, we next studied the sensitivity of c-jun À/À MEFs and of those expressing a c-Jun protein in which the main JNK phosphorylation target sites were mutated (Ser 63/73 to Ala 63/73 ; c-junAA). Both cell types showed intermediate sensitivity between wild-type (wt) and jnk1/2 À/À MEFs (IC 50 ¼ 60 nM) (Figure 6a, b) . Next, we analysed the effect of SB203580 and PD98059, a MEK1 inhibitor that blocks ERK activation, on the response of jnk1/2 À/À cells to Aplidint. As expected from the lack of JNK expression, SB203580, but not PD98059, increased resistance to the drug in jnk1/2 À/À cells much less (1.8 times) than in wt MEFs (6.3 times) or MDA-MB-231 (2.9 times) cells (Figure 6c ), indicating the involvement of JNK, but not ERK, in Aplidint action. As JNK activates AP-1 mainly by phosphorylating c-Jun, we studied AP-1 activity in wt, jnk1/2 À/À and c-jun À/À MEFs upon Aplidint treatment. In comparison to wt MEFs, AP-1 activation was lower in jnk1/2 À/À and absent in c-jun À/À cells (Figure 6d ). This result is consistent with recent reports that c-Jun is phosphorylated by other kinase(s) apart from JNK (Morton et al., 2003) . Moreover, jnk1/2 À/À MEFs contained higher basal levels of phospho-Ser 63 -c-Jun than wt MEFs, although the increase upon Aplidint addition was higher in wt cells (Figure 7a) .
We analysed the activation by Aplidint of p38MAPK and ERK, the phosphorylation of c-Jun, and the effect of SB203580 and PD98059 in jnk1/2 À/À MEFs. In agreement with previous reports in human leukemia HL60 cells (Wang et al., 2000) , results with SB203580 indicated a negative feedback loop from a p38MAPK/ JNK target to a positive upstream regulator of JNK and ERK in wt MEFs (Figure 7b ). SB203580 inhibited p38MAPK activation by Aplidint in wt but not in jnk1/ 2 À/À MEFs. Analogously to the recent report that in jnk1/2 À/À MEFs ERK mediates the phosphorylation of c-Jun at Ser63 and Ser 73 by EGF and phorbol ester (Morton et al., 2003) , our data show that in jnk1/2 À/À MEFs, ERK and particularly an unidentified kinase phosphorylate c-Jun in its Ser63 residue in response to Aplidint (Figure 7b) .
Finally, we examined whether Aplidint action depended on the cell proliferation status. To this end, three nontumoral human cells (IMR90 lung fibroblasts, HMEC-1 dermal microvascular cells and MCF10A breast epithelial cells) were treated with 5, 50 or 500 nM Aplidint either when made quiescent by serum removal or when growing in 10% serum containing medium. In all cases, proliferative cells were more sensitive to Aplidint (Figure 8a) . Remarkably, the level of JNK activation by Aplidint correlated directly with the sensitivity to the drug: both were higher in growing than in quiescent cells (Figure 8b ).
Discussion
In this work, we have examined the molecular mechanism of action of Aplidint, an antitumor agent of marine origin presently in phase II clinical trials. Aplidint rapidly triggers an apoptotic process that does not require its continuous presence, and that is accompanied by the transient induction of a series of early response genes of the JUN and FOS families and of p65/RELA. This leads to the activation of AP-1 and NF-kB factors, which are known regulators of cell survival and growth that promote apoptosis depending on the stimulus, cellular context and combination of incoming signals. In addition, Aplidint represses c-MYC expression.
Our data identify JNK among the kinases activated by Aplidint (EGFR, Src, JNK, p38) as a key À/À MEFs. p38MAPK deficiency was tested using an antibody that recognizes all isoforms component of the apoptotic process induced by the drug. The lack of specificity of kinase inhibitors, exemplified by the dual inhibition of p38MAPK and JNK by SB203580 in MDA-MB-231 cells (Cuadrado et al., 2003) , led us to investigate Aplidint action in genetically deficient cells. By using a series of MEFs lacking one or more kinases, JNK was found to be critical for Aplidint action. JNK was originally characterized and has long been considered as the main enzyme responsible for c-Jun protein phosphorylation in its Ser 63/73 residues (Davis, 2000) . However, we now know that JNK phosphorylates other substrates, and also that other kinases can phosphorylate c-Jun in these and other residues (Morton et al., 2003) . The finding that cells lacking c-Jun protein or expressing a protein lacking Ser 63/73 residues display reduced but still considerable sensitivity to Aplidint, higher than those with no JNK, indicates that phosphorylation of c-Jun and also of other uncharacterized JNK targets is involved in the apoptotic process. Among them, Elk-1 and ATF-2, involved in AP-1 activation, are obvious candidates. This is reminiscent of the situation in liver cells, in which molecules other than c-Jun mediate the modulation by JNK of the apoptosis induced by tumor necrosis factor (Liedtke et al., 2002) . The biological relevance of these data is shown by the fact that JNK is required for stressinduced activation of the mitochondrial death signaling (Tournier et al., 2000) , and by the recent report that c-Jun phosphorylation by JNK is essential for the relief of histone deacetylase-dependent suppression of the transcriptional activity of c-Jun (Weiss et al., 2003) .
By using kinase inhibitors, we showed that JNK/ p38MAPK activation, but not that of Src or PI3 K activity, precedes EGFR phosphorylation/activation in the cascade of Aplidint effects. Studies using jnk1/2 À/À cells confirmed that JNK activation is required for that of EGFR. Since previous data indicated that JNK/ p38MAPK activation by the drug is enhanced by EGFR and Src (Cuadrado et al., 2003) , there seems to be a positive feedback among these kinases that probably promote apoptosis.
Concordantly with our findings, tumor necrosis factor-a and other agents activate members of the mitogen-activated protein kinases and NF-kB (JanssenHeininger et al., 2000, and references therein). Moreover, JNK has been proposed to mediate NF-kB activation by oxidants (Janssen-Heininger et al., 1999) . It is remarkable that IkBa degradation, the classical mechanism of NF-kB activation, was not detected upon Aplidint addition. However, alternative mechanisms of NF-kB activation have been proposed (Bowie and O'Neill, 2000) . For instance, IkBb degradation instead of that of IkBa may result in NF-kB activation (Newton et al., 1999; Biswas et al., 2003) , and oxidative stress induces NF-kB nuclear translocation without degradation of IkBa (Canty et al., 1999) . Likewise, neither IKK activation nor IkBatphosphorylation at Ser 32/36 are involved in the activation of NF-kB by ultraviolet C irradiation (Li and Karin, 1998) . In the case of Aplidint, the finding of a weak phosphorylation of IkBa at Ser 32/36 and the lack of phosphorylation at Tyr 42 , which is induced by some oxidative stresses (Imbert et al., 1996; Singh et al., 1996) , suggest that the induction of p65/ RELA protein by the drug could be important for NF-kBactivation.EmphasizingthecomplexityofAplidint action, the induction of JUN, FOS and p65/RELA genes is variably sensitive to the inhibition of EGFR, Src and JNK/p38MAPK.
From these data, JNK and probably AP-1 and NFkB seem to be critical for Aplidint-induced apoptosis. Besides c-Jun, other proteins interacting with or encoded by AP-1/NF-kB regulated genes may also be involved. In addition, the importance of c-MYC repression for the induction of apoptosis remains to be established. Microarray-based procedures are currently underway to help in their characterization.
Since NF-kB is commonly considered a survival factor that inhibits apoptosis through the activation of antiapoptotic genes, its activation by Aplidint is puzzling. However, recent data indicate that NF-kB has a proapoptotic or antiapoptotic function depending on the nature of the apoptotic stimulus and cell type (Kaltschmidt et al., 2000) and induction by NF-kB of proapoptotic proteins has also been reported (Kucharczak et al., 2003, review) . Although the proapoptotic effect of NF-kB in some contexts remains to be characterized, there are reports that it suppresses JNK activity (Kucharczak et al., 2003 and reference therein) , and in this regard NF-kB activation by Aplidint could ameliorate JNK activation. If true, this would fit with the hypothesis that NF-kB activation by several chemotherapeutic agents decreases their effectiveness (Garg and Aggarwal, 2002) .
Aplidint has preferential cytotoxicity against tumoral versus nontumoral cells (Gajate et al., 2003) . Autocrine growth stimulation is characteristic of cancer cells (Hanahan and Weinberg, 2000) , which may explain why MDA-MB-231 and many other cell lines of tumoral origin survive or even grow in the absence of serum or exogenous growth factors. We showed that three human normal, nontumoral cell types are less sensitive to the cytotoxic action of Aplidint when made quiescent by serum starvation than when they proliferate in serumcontaining medium. This result suggests that Aplidint might have a preferential killing action against actively cycling cells in vivo, which may partly explain its low toxicity profile (Raymond et al., 2001) . Importantly, the molecular basis for this behavior points to a crucial role of JNK, since the differential potency of Aplidint in these two conditions correlates directly with the level of JNK activation.
In conclusion, by identifying genes of the JUN and FOS families and p65/RELA and AP-1 and NF-kB factors as targets of Aplidint, and JNK as a primary and crucial mediator of its apoptosis-inducing activity, we have elucidated the mechanism of action of this novel and extremely potent antitumor drug under clinical study. Ongoing studies are attempting to characterize relevant JNK targets as well as other putative genes mediating Aplidint action.
Materials and methods
Cell lines and reagents
Human breast cancer MDA-MB-231 and MCF7 cells, dermal microvascular HMEC-1 cells and IMR90 human diploid fibroblasts were grown in Dulbecco's modified Eagles' medium (DMEM) supplemented with 10% FCS and 1 mM glutamine (all from GIBCO-Invitrogen, Paisley, UK). MCF10A normal human mammary epithelial cells (supplied by Dr D Salomon, National Cancer Institute, Bethesda, MD, USA), were cultured in a mixture (1 : 1) of DMEM:F12 media supplemented with 5% horse serum, 20 ng/ml human recombinant EGF (Upstate Biotechnology, Lake Placid, NY, USA) and 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml sodium selenite (all from GIBCO-Invitrogen) and 0.5 mg/ml hydrocortisone. Wt and genetically deficient mouse embryo fibroblasts (MEFs) for jnk1 and jnk2 and c-jun, and those expressing c-junAla 63/73 were donated by Dr E Wagner (Institut fu¨r Molekulare Pathologie, Vienna, Austria); MEFs lacking src, fyn and yes were obtained from the American Type Culture Collection, and those lacking p38MAPKa were donated by Dr A Nebreda (European Molecular Biology Laboratory, Heidelberg, Germany).
Aplidint is manufactured by Pharma Mar SA (Madrid, Spain). Stock solutions were freshly prepared in dimethylsulfoxide and diluted in the cell culture to final concentrations as indicated. Lactacystin, E64, LY294002 and PD98059 were from Sigma Chemical Co. (St Louis, MO, USA), and SB203580, AG1478, MG132 and PP2 were from Calbiochem-Merck Biosciences (Darmstadt, Germany).
Northern blot
To prepare total RNA from cells we used Tri-Reagent according to the manufacturer's instructions (Molecular Research Center, Cincinnati, OH, USA). RNAs were fractionated in formaldehyde agarose gels and blotted onto nylon membranes (Nytran; Schleicher and Schuell, Dassel, Germany) following standard methods (Sambrook et al., 1989) . As control for RNA loading, the filters were stained with 0.02% methylene blue in 0.3 M sodium acetate. Radioactive probes were prepared by the random priming procedure using ready-to-go kit (Amersham Pharmacia Biotech).
Immunoprecipitation and Western blot analysis
To study the effect of Aplidint on the activity of kinases (p38MAPK, JNK, ERK), cells were preincubated for 24 h in serum-free medium. For immunoprecipitation cells were lysed in modified RIPA buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS, 1 mM Na 3 VO 4 , 25 mM b-glycerolphosphate, 100 mM NaF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF). Lysates were precleared by incubation with protein G-Sepharose at 41C for 30 min and then incubated overnight with the corresponding antibody (1 mg/ml). After 1 h incubation with protein G-sepharose, immune complexes were washed three times in the same RIPA buffer lacking deoxycholic acid and SDS and three times with HNTG (50 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.1% SDS, 1 mM Na 3 VO 4 , 10mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF) and electrophoresed in 8% acrylamide gels. For Western blot analysis cell protein extracts were prepared following standard procedures (Sambrook et al., 1989) . Protein extracts were electrophoresed in 8 or 12% polyacrylamide gels and transfered onto nitrocellulose (Immobilon P, Millipore) membranes. The filters were washed, blocked with 5% BSA in Tris-buffered saline (25 mM Tris pH 7.4, 136 mM NaCl, 2.6 mM KCl, 0.5% Tween-20), and incubated overnight at 41C with the appropriate antibody (1 : 1000 dilution). Blots were washed three times for 10 min in PBS þ 0.1% Tween-20 and incubated with HRPconjugated secondaries antibodies for 1 h at room temperature. Blots were developed by a peroxidase reaction using the ECL detection system (Amersham-Pharmacia Biotech).
Electrophoretic mobility shift assays
Nuclear extracts were prepared as previously described (Lo´pez Ongil et al., 1998) . Oligonucleotide sequences were as follows. 0 . Primers were annealed by incubation for 5 min at 851C in 10 mM phosphate buffer pH 7.0 and slowly cooled down to room temperature. Double-stranded oligonucleotides were labeled with [g-32 P]ATP at the 5 0 -end with T4 polynucleotide kinase (Promega Co.). For protein-oligonucleotide binding reactions end-labeled oligonucleotide probes were incubated with 7 mg of nuclear extract and 1 mg of poly(dI-dC)-poly(dI/dC) in binding buffer (4% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5) at room temperature for 30 min. Protein-DNA complexes were separated by electrophoresis in a 6% nondenaturing polyacrylamide gel in 0.25 Â TBE buffer at 20 mA. The gels were dried under vacuum and exposed to X-ray film. The specificity of binding was also examined by competition with the unlabeled oligonucleotide.
Transactivation assays
Cells were transfected at around 50% confluence in 6-cm dishes with 5 mg of DNA using Lipofectamine (Invitrogen). We used 3 mg of reporter plasmid 3 Â NF-kB-tk-Luc plasmid (containing three copies of the binding site for NF-kB transcription factor, donated by Dr MA In˜iguez, Centro de Biologı´a Molecular, Madrid, Spain), 0.5 mg of pCH110, a bgalactosidase expression vector used as an internal control to normalize for variations in transfection efficiency, and the pSG5 vector as carrier to adjust the total amount of DNA. After overnight incubation with lipofectamine-DNA mixtures, transfected cells were washed twice in PBS and incubated with fresh medium supplemented with 0.5% FCS. Each treatment was carried out in triplicate cultures. Cell extracts were prepared by freeze-thawing in 0.25 M Tris-HCl (pH 7.5) and used for luciferase assays.
Antibodies
Antibodies used were: mouse monoclonal antibodies anti-JNK1, anti-p38MAPK, anti-ERK, anti-MYC, anti-b-actin, anti-human EGFR were from Santa Cruz; anti-phospho-JNK1, anti-phospho-p38MAPK, anti-phospho-ERK, from New England Biolabs (Beverly, MA, USA) and anti-phospho-tyrosine from Transduction Laboratories/BD Biosciences (Heidelberg, Germany).
Cell survival and proliferation assays
DNA synthesis measurements and crystal violet staining assays were done as described (Cuadrado et al., 2003) . [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl] tetrazolium bromide (MTT) assays were performed following the manufacturer's instructions (MTT cell proliferation Kit I, Roche Diagnostics, Mannheim, Germany).
